Comparative Pharmacology
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE PRESERVATIVE FREE versus VESICARE LS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE PRESERVATIVE FREE versus VESICARE LS.
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE) vs VESICARE LS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3) in the gastrointestinal tract, producing antispasmodic effects by reducing smooth muscle contractions.
Competitive antagonist at muscarinic acetylcholine receptors (M1–M5), with high selectivity for M3 receptors in the bladder detrusor muscle. Reduces involuntary bladder contractions and increases bladder capacity.
20 mg intramuscularly every 4-6 hours.
5 mg orally once daily; may increase to 10 mg once daily.
None Documented
None Documented
5-8 hours; may be prolonged in elderly or patients with hepatic impairment
Terminal elimination half-life: 45 hours (range 32–68 h). Extended half-life allows once-daily dosing; steady-state reached in ~10 days.
Renal (approximately 50-80% as unchanged drug and metabolites), biliary/fecal (minor, <10%)
Renal: 68% (unchanged drug ~59%, metabolites ~9%), Fecal: 24% (metabolites), Biliary: negligible.
Category A/B
Category C
Anticholinergic
Anticholinergic